Edition:
United States

Biotechnology & Medical Research

Page 1

Merrimack names Richard Peters as president and CEO

Wednesday, 18 Jan 2017 07:30am EST

Merrimack Pharmaceuticals Inc : Merrimack names Richard Peters as president and CEO . Merrimack Pharmaceuticals Inc - Peters replaces Gary Crocker, chairman and interim president and CEO .Merrimack Pharmaceuticals Inc - Gary Crocker will remain chairman of board.

Ixico appoints Giulio Cerroni as CEO

Tuesday, 17 Jan 2017 02:00am EST

Ixico Plc :Appointment of Giulio Cerroni as CEO.

Nivalis therapeutics announces corporate restructuring

Thursday, 12 Jan 2017 04:10pm EST

Nivalis Therapeutics Inc : Nivalis Therapeutics announces corporate restructuring . Nivalis Therapeutics Inc says intends to complete a reduction in force affecting 25 employees . Nivalis Therapeutics Inc - Board of directors has approved a restructuring plan as part of company's initiative to explore strategic alternatives . Says estimates that it will incur cash severance costs of approximately $3 million . Nivalis Therapeutics - Co estimates it will incur cash severance costs of approximately $3 million, which are expected to be paid during first half of 2017 . Nivalis Therapeutics Inc says Congleton will be stepping down from his role as president and chief executive officer effective January 15, 2017 . Says reduction in force is intended to preserve company's cash while it assesses various strategic alternatives . Nivalis Therapeutics - Co currently projects that it will have approximately $45-$47 million of net cash available for potential strategic transaction . Nivalis Therapeutics - Reduction in workforce includes Jon Congleton, president & CEO, and David Rodman, M.D., chief medical officer .Board has appointed Michael Carruthers, co's chief financial officer, as interim president, effective Jan 15, 2017.

Invitae appoints Sean George chief executive officer

Monday, 9 Jan 2017 07:30am EST

Invitae Corp : Sean George appointed as chief executive officer .Current chairman and chief executive officer Randy Scott will become executive chairman of board of directors.

Insys Therapeutics announces retirement of Dr. John Kapoor as CEO

Monday, 9 Jan 2017 06:50am EST

Insys Therapeutics Inc : Insys Therapeutics announces retirement of Dr. John n. Kapoor as ceo and chairman; appoints Dr. Santosh vetticaden as interim CEO and Steven Meyer as chairman of the board .Insys Therapeutics inc - Kapoor will remain a member of board.

Immunomedics announces reconstituted board and leadership succession plan

Monday, 9 Jan 2017 06:00am EST

Immunomedics Inc : Immunomedics announces reconstituted board of directors and leadership succession plan . Immunomedics Inc - Announces chairman and CEO succession plans . Immunomedics Inc - Effective June 30, 2017, Jason Aryeh will assume role of chairman of Immunomedics board. . Immunomedics Inc - David M. Goldenberg, current chairman, will transition his role, effective June 30, 2017 .Immunomedics Inc - Board will immediately initiate a search for a new CEO.

Chengzhi Shareholding's president resigns due to change in job role

Monday, 9 Jan 2017 04:43am EST

Chengzhi Shareholding Co Ltd <000990.SZ> :Says President Zheng Chengwu resigns due to change in job role.

MDxHealth expects to achieve upgraded guidance for FY 2016 and appoints new CFO

Monday, 9 Jan 2017 01:00am EST

MDxHealth SA : MDxHealth announces preliminary update on 2016 results and appointment of CFO . Expects to achieve upgraded market guidance for FY 2016 financial results following continued strong growth of ConfirmMDx and early adoption of SelectMDx during year . Underlying earnings before interest, taxes, depreciation and amortization (ebidta) are also expected to improve compared to 2015 . Full-Year 2016 results will reflect initial sales of company's SelectMDx for prostate cancer "liquid biopsy" test . Co previously upgraded its expected full-year revenue growth to more than 60 percent compared with its initial guidance predicting growth of 30-50 percent over 2015 .MDxHealth announces appointment of Jean-Marc Roelandt as chief financial officer with effect from January 15, 2017.

Oncogenex Pharmaceuticals and Achieve Life Science announce definitive merger agreement

Thursday, 5 Jan 2017 04:30pm EST

Oncogenex Pharmaceuticals Inc : Oncogenex Pharmaceuticals Inc and Achieve Life Science, Inc announce definitive merger agreement . Oncogenex - upon completion of proposed merger, achieve's equity holders are expected to own 75 pct of combined company's outstanding shares . Oncogenex Pharmaceuticals Inc - combined company's executive management team will be led by Rick Stewart, chairman of Achieve . Oncogenex Pharmaceuticals - expected to distribute to its stockholders contingent value rights (CVRS) for 80 pct of any net proceeds of certain payments . Oncogenex Pharmaceuticals Inc - board of directors of combined company is expected to consist of seven members . Following completion of merger, Oncogenex Pharmaceuticals Inc ill be renamed Achieve Life Sciences Inc . Oncogenex - after completion, current stockholders of oncogenex are expected to own remaining 25 pct of combined company's outstanding shares . Oncogenex Pharmaceuticals Inc - "efforts will continue to establish a strategic partnership to further development of apatorsen" .Oncogenex Pharmaceuticals Inc - transaction has been approved unanimously by boards of directors of both companies.

Targovax appoints Erik Digman Wiklund CFO

Thursday, 5 Jan 2017 01:00am EST

Targovax ASA : Announces appointment of Erik Digman Wiklund CFO . Erik Digman Wiklund will take up the position in April 2017 .Previous CFO, Oystein Soug, was appointed as Targovax's CEO on Nov. 2 2016.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary